These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36545240)

  • 1. Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation.
    Burmester DR; Madsen MK; Szabo A; Aripaka SS; Stenbæk DS; Frokjaer VG; Elfving B; Mikkelsen JD; Knudsen GM; Fisher PM
    Compr Psychoneuroendocrinol; 2023 Feb; 13():100163. PubMed ID: 36545240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.
    Stenbæk DS; Madsen MK; Ozenne B; Kristiansen S; Burmester D; Erritzoe D; Knudsen GM; Fisher PM
    J Psychopharmacol; 2021 Apr; 35(4):459-468. PubMed ID: 33501857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fibrinolytic system: A new target for treatment of depression with psychedelics.
    Idell RD; Florova G; Komissarov AA; Shetty S; Girard RB; Idell S
    Med Hypotheses; 2017 Mar; 100():46-53. PubMed ID: 28236848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study.
    Mason NL; Szabo A; Kuypers KPC; Mallaroni PA; de la Torre Fornell R; Reckweg JT; Tse DHY; Hutten NRPW; Feilding A; Ramaekers JG
    Brain Behav Immun; 2023 Nov; 114():299-310. PubMed ID: 37689275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals.
    McCulloch DE; Madsen MK; Stenbæk DS; Kristiansen S; Ozenne B; Jensen PS; Knudsen GM; Fisher PM
    J Psychopharmacol; 2022 Jan; 36(1):74-84. PubMed ID: 34189985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
    Madsen MK; Fisher PM; Burmester D; Dyssegaard A; Stenbæk DS; Kristiansen S; Johansen SS; Lehel S; Linnet K; Svarer C; Erritzoe D; Ozenne B; Knudsen GM
    Neuropsychopharmacology; 2019 Jun; 44(7):1328-1334. PubMed ID: 30685771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
    Carhart-Harris RL; Bolstridge M; Rucker J; Day CM; Erritzoe D; Kaelen M; Bloomfield M; Rickard JA; Forbes B; Feilding A; Taylor D; Pilling S; Curran VH; Nutt DJ
    Lancet Psychiatry; 2016 Jul; 3(7):619-27. PubMed ID: 27210031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
    Leger RF; Unterwald EM
    J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
    Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ
    Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors.
    Strumila R; Nobile B; Korsakova L; Lengvenyte A; Olie E; Lopez-Castroman J; Guillaume S; Courtet P
    Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience.
    Madsen MK; Stenbæk DS; Arvidsson A; Armand S; Marstrand-Joergensen MR; Johansen SS; Linnet K; Ozenne B; Knudsen GM; Fisher PM
    Eur Neuropsychopharmacol; 2021 Sep; 50():121-132. PubMed ID: 34246868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained effects of single doses of classical psychedelics in humans.
    Knudsen GM
    Neuropsychopharmacology; 2023 Jan; 48(1):145-150. PubMed ID: 35729252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.
    Johnson MW; Garcia-Romeu A; Cosimano MP; Griffiths RR
    J Psychopharmacol; 2014 Nov; 28(11):983-92. PubMed ID: 25213996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
    Galvão-Coelho NL; Marx W; Gonzalez M; Sinclair J; de Manincor M; Perkins D; Sarris J
    Psychopharmacology (Berl); 2021 Feb; 238(2):341-354. PubMed ID: 33427944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of saliva and gingival crevicular fluid soluble urokinase plasminogen activator receptor (suPAR), galectin-1, and TNF-α levels in periodontal health and disease.
    Taşdemir İ; Erbak Yılmaz H; Narin F; Sağlam M
    J Periodontal Res; 2020 Oct; 55(5):622-630. PubMed ID: 32166745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychedelic perceptions: mental health service user attitudes to psilocybin therapy.
    Corrigan K; Haran M; McCandliss C; McManus R; Cleary S; Trant R; Kelly Y; Ledden K; Rush G; O'Keane V; Kelly JR
    Ir J Med Sci; 2022 Jun; 191(3):1385-1397. PubMed ID: 34131812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation.
    Johnson MW
    Curr Top Behav Neurosci; 2022; 56():213-227. PubMed ID: 35704271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psilocybin and Eugenol Reduce Inflammation in Human 3D EpiIntestinal Tissue.
    Robinson GI; Li D; Wang B; Rahman T; Gerasymchuk M; Hudson D; Kovalchuk O; Kovalchuk I
    Life (Basel); 2023 Dec; 13(12):. PubMed ID: 38137946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.